-
-
[1] Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma[J]. Mol Cancer Ther, 2007, 6(12 Pt 1):3314-3322. [2] Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated resultsfrom a phase 1 study[J]. Lancet Oncol, 2012, (13): 1011-1019. [3] Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013, (368):2385-2394. [4] Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from profile 1 014[J]. J Clin Oncol, 2016, 34(24):2858-2865. doi: 10.1200/JCO.2015.63.5888 [5] Maka VV, Krishnaswamy UM, Anil KN, et al. Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive nonsmall-cell lung cancer after crizotinib therapy[J]. Oxf Med Case Rep, 2014, 2014(1):11-12. doi: 10.1093/omcr/omu004 -
下载:
点击查看大图
图(3)
计量
- 文章访问数: 105
- HTML全文浏览量: 22
- PDF下载量: 1
- 被引次数: 0
